Somatostatin-14 and its analog octreotide exert a cytostatic effect on gh3 rat pituitary tumor cell proliferation via a transient g0/g1 cell cycle block

Endocrinology

Volumn 136, Issue 10, 1995, Pages 4174-4181

  Cheung, N Wah ^a   Boyages, Steven C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN 14;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; GROWTH REGULATION; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMAL; CELL DIVISION; G0 PHASE; G1 PHASE; OCTREOTIDE; PITUITARY NEOPLASMS; RATS; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0028982707     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/endo.136.10.7664634     Document Type: Article

References (43)

1. Battershill PE, Clissold SP 1989 Octreotide. Drugs 38:658-702
2. Tsuzaki S, Moses AC 1990 Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-1 in FRTL-5 cells. Endocrinology 126:3131-38
3. 3) proliferation in vitro, J Endocrinol Invest 13:657-662
4. Lamberts SWJ, Reubi JC, Uiterlinden P, Zuiderwijk J, van den Werff P, van Hal P 1986 Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology 118:2188-2194
5. Hof land LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SWJ 1992 Dissociation of the antiproliferative, antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumour cells. Endocrinology 131:571-577
6. Seytono-Han B, Henkelman MS, Foekens JA, Klijn JGM 1987 Direct inhibitory effect of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47:1566-1570
7. Pagliacci MC, Tognellini R, Grignani F, Nicoletti 11991 Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters, ap-optotic cell death. Endocrinology 129:2555-2562
8. Liebow C, Reilly C, Serrano M, Schally AV 1989 Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86:2003-2007
9. Ain K, Taylor K 1994 Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1097-1102
10. Dy D, Whitehead RH, Morris DL 1992 SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 52:917-923
11. Redding TW, Schally AV 1984 inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248-252
12. Siegel RA, Tolcsvai L, Rudin M 1988 Partial inhibition of the growth of transplanted Dunning rat prostate tumors with the long-acting somatostatn analogue Sandostatin (SMS 201-995). Cancer Res 48: 4651-4655
13. Mozell EJ, Woltering EA, O'Dorisio TA 1991 Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy. Cancer therapy. Dis Month 37:784-788
14. Reubi JC, Kvols L, Krenning E, Lamberts SWJ 1990 Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39:78-81
15. Schally AV 1988 Oncological applications of somatostatin analogues. Cancer Res 48:6977-6985
16. Schonbrunn A, Tashjian AH 1978 Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 253:6473- 6483
17. Dorflinger LJ, Schonbrunn A 1983 Somatostatin inhibits basal and vasoactive intestinal peptide-stimulated hormone release by different mechanisms in GH pituitary cells. Endocrinology 113: 1551-1558
18. Smerdely P, Pitsiavis V, Boyages SC 1993 Evidence that the inhibitory effects of iodide on thyroid cell proliferation are due to arrest of the cell cycle at G0G1 and G2 m phases. Endocrinology 133:2881-2888
19. Smerdely P, Pitsiavis V, Boyages SC 1993 Methimazole inhibits FRTL5 thyroid cell proliferation by inducing S-phase arrest of the cell cycle. Endocrinology 133:2403-2406
20. Pardee AB 1989 G1 events and regulation of cell proliferation. Science 246:603-608
21. Berridge MJ 1993 Inositol triphosphate and calcium signalling. Nature 361:315-325
22. Todisco A, Campbell V, Dickinson CJ, DelValle J, Yamada T 1994 Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding. Am J Physiol 267:G245-G253
23. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB 1994 All five cloned human somatostatin receptors (hSSTRl-5) are functionally coupled to adenyl cyclase. Biochem Biophys Res Com-mun 198:605-612
24. 3 expresses two somatostatin receptor subtypes that inhibit adenyl cyclase: functional expression of rat somatostatin receptor subtypes 1 and 2 in human embryonic kidney 293 cells. Mol Pharmacol 45:402-409
25. Bruno JF, Xu Y, Berelowitz M 1994 Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells. Biochem Biophys Res Commun 202:1738-1743
26. 2+ mobilization. Biochem Biophys Res Commun 200:986-992
27. Kagimoto S, Yamada Y, Kubota A, Someya Y, Ihara Y, Yasuda K, Kozasa T, Imura H, Seino S, Seino Y 1994 Human somatostatin receptor, SSTR2, is coupled to adenyl cyclase in the presence of Gi-αl protein. Biochem Biophys Res Commun 202: 1188-1195
28. Coy DH, Murphy WA, Raynor K, Reisine T 1993 The new pharmacology of somatostatin and its multiple receptors. J Pediatr Endocrinol 6:205-209
29. Yasuda K, Rens-Domiano S, Breder C, Law SF, Saper C, Reisine T, Bell GI 1992 Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem 267:20422-20428
30. Reisine T, Kong H, Raynor K, Law SF, Theveniau M, Tallent M, Hines J, Yasuda K, Bell GI 1993 Molecular biology of somatostatin receptors. In: Melmed S (ed) Molecular and Clinical Advances in Pituitary Disorders-1993, Proceedings of the 3rd International Pituitary Congress. Endocrine Research and Education, Beverly Hills, pp 293-297
31. Daar I, Nebreda AR, Yew N, Sass P, Paules R, Santos E, Wigler M, Vande Woude GF 1991 The ras oncoprotein and M-phase activity. Science 253:74-76
32. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C 1994 Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR22. Proc Natl Acad Sci USA 91:2315-2319
33. Mascardo RN, Sherline P 1982 Somatostatin inhibits rapid centro-somal separation and cell proliferation induced by epidermal growth factor. Endocrinology 111:1394-1396
34. Kutz K, Nuesch E, Rosenthaler J 1986 Pharmacockinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol [Suppl 1191 21: 65-72
35. Marbach P, Andres H, Azria M, Bauer W, Briner U, Bucheit KH, Doepfner W, Lemaire M, Petcher TJ, Pless J, Reubi JC 1988 Chemical structure, pharmacodynamic profile and pharmacokinetics of SMS 201-995 (Sandostatin). In; Lamberts SWJ (ed) Sandostatin in the Treatment of Acromegaly. Springer-Verlag, Berlin and Heidelberg, pp 53-60
36. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G 1989 Disposition of Sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos 17:699-703
37. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J 1993 Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217-223
38. Ebert M, Friess H, Beger HG, Buchler MW 1994 Role of octreotide in the treatment of pancreatic cancer. Digestion [Suppl 1] 55:48-51
39. Verhelst J, De Longueville M, Ongena P, Denis L, Mahler C 1994 Octreotide in advanced pancreatic cancer relapsing under hormonal control. Acta Urol Belg 62:83-88
40. Presky DH, Schonbrunn A 1988 Somatostatin pretreatment increases the number of somatostatin receptors in GH pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 263:714-721
41. McMartin C, Purdon GE 1978 Early fate of somatostatin in the circulation of the rat after intravenous injection. J Endocrinol 77:67-74
42. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M 1979 Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50-53
43. Pless J, Bauer W, Briner U, Doepfner W, Marbach P, Maurer R, Petcher TJ, Reubi JC, Vonderscher J 1986 Chemistry and pharmacology of SMS 201-995, a long acting octapeptide analogue of somatostatin. Scand J Gastroenterol [Suppl 1191 21:54-64